Calciscon develops and markets diagnostic devices for the assessment of calcification-related cardiovascular (CV) disease. CV disease is the leading cause of death worldwide, and vascular calcification is a most important driver of CV disease. Calciscon has developed and markets the T50 test, a novel and unique measurement of calcification. This medical information is critical to enable individualized care, and pivotal to reduce calcification and prevent cardiovascular disease. The T50 addresses a multi-billion market opportunity, and Calciscon will initially target patients with advanced chronic kidney disease (CKD), the patient group with the highest rate of calcification-related CV events (20x higher then normal population). The T50 test first enables the doctor to identify highest-risk patients, and then drives the selection of the most effective therapy to critically reduce calcification, to improve patient CV prognosis.
View Top Employees from Calciscon AGWebsite | https://www.calciscon.com/ |
Revenue | $5 million |
Funding | $650000 |
Employees | 9 (6 on RocketReach) |
Founded | 2013 |
Address | 46 Aarbergstrasse, Biel/Bienne, Bern 2503, CH |
Phone | +41 32 530 88 60 |
Technologies | |
Industry | Medical Equipment Manufacturing, Hospitals & Clinics, Diagnostic Equipment, Healthcare, Clinics/Outpatient Services |
SIC | SIC Code 80 Companies, SIC Code 809 Companies |
NAICS | NAICS Code 62 Companies, NAICS Code 6214 Companies, NAICS Code 62149 Companies, NAICS Code 621 Companies, NAICS Code 621492 Companies |
Looking for a particular Calciscon AG employee's phone or email?
The Calciscon AG annual revenue was $5 million in 2024.
Vincent Linder is the CEO of Calciscon AG.
6 people are employed at Calciscon AG.
Calciscon AG is based in Biel/Bienne, Bern.
The NAICS codes for Calciscon AG are [62, 6214, 62149, 621, 621492].
The SIC codes for Calciscon AG are [80, 809].